ZLAB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ZLAB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Zai Lab's Other Stockholders Equity for the quarter that ended in Dec. 2023 was $0.0 Mil.
Zai Lab's quarterly Other Stockholders Equity declined from Jun. 2023 ($0.0 Mil) to Sep. 2023 ($0.0 Mil) but then increased from Sep. 2023 ($0.0 Mil) to Dec. 2023 ($0.0 Mil).
Zai Lab's annual Other Stockholders Equity stayed the same from Dec. 2021 ($0.0 Mil) to Dec. 2022 ($0.0 Mil) but then declined from Dec. 2022 ($0.0 Mil) to Dec. 2023 ($0.0 Mil).
The historical data trend for Zai Lab's Other Stockholders Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zai Lab Annual Data | |||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||||||
Other Stockholders Equity | Get a 7-Day Free Trial | - | - | - | - | - |
Zai Lab Quarterly Data | ||||||||||||||||||||
Dec18 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Other Stockholders Equity | Get a 7-Day Free Trial | - | - | - | - | - |
Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity
Thank you for viewing the detailed overview of Zai Lab's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Harald Reinhart | officer: Chief Medical Officer | 4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210 |
Edmondson Frazor Titus Iii | officer: Chief Legal Officer | 4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210 |
Ying Du | director, officer: Chairwoman & CEO | C/O ZAID LAB LIMITED, 4560 JINKE ROAD, BLDG. 1, 4F, PUDONG, SHANGHAI F4 201210 |
Rafael Amado | officer: See Remarks | 210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080 |
Joshua L Smiley | officer: Chief Operating Officer | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Yajing Chen | officer: Chief Financial Officer | 314 MAIN STREET, 4TH FLOOR, SUITE 100, CAMBRIDGE MA 02142 |
Michel Vounatsos | director | BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142 |
Peter Wirth | director | 37 HANCOCK STREET, BOSTON MA 02114 |
John D Diekman | director | C/O 5 AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
William Lis | director | PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Richard Gaynor | director | C/O NEON THERAPEUTICS, 40 ERIE STREET, SUITE 110, CAMBRIDGE MA 02139 |
Tao Fu | director, officer: President & COO | 3175 HANOVER STREET, PALO ALTO CA 94304 |
Scott W Morrison | director | C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT SUITE 101, SOUTH SAN FRANCISCO CA 94080 |
Cho William Ki Chul | officer: Chief Financial Officer | 4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210 |
Kai-xian Chen | director | 4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210 |
From GuruFocus
By Business Wire • 12-13-2023
By Marketwired • 10-18-2023
By Marketwired • 10-26-2023
By Marketwired • 06-30-2023
By Marketwired • 06-28-2023
By Marketwired • 07-09-2023
By Marketwired • 07-17-2023
By PRNewswire • 07-12-2023
By Marketwired • 08-07-2023
By PRNewswire • 07-03-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.